Saturday 17 October 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.58
0.04
−6.45%
Follow APRE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
(30.12) | (17.31) | (18.52) | — | — | — | — | — | — |
P/S ratio |
19.45 | 12.06 | 0.00 | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(64.83) | (37.79) | (40.55) | — | — | — | — | — | — |
P/Operating CF |
(1.88) | (5.16) | (4.84) | — | — | — | — | — | — |
P/B ratio |
0.45 | 0.94 | 1.07 | — | — | — | — | — | — |
Price to Tangible BV |
0.45 | 0.94 | 1.07 | — | — | — | — | — | — |
EV/Sales |
(31.65) | (3.14) | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
0.68 | 0.33 | 0.23 | — | — | — | — | — | — |
EV/Operating CF |
0.70 | 0.35 | 0.29 | — | — | — | — | — | — |
EV/FCF |
0.70 | 0.35 | 0.29 | — | — | — | — | — | — |
Quick Ratio |
5.28 | 6.80 | 4.93 | 8.99 | 7.25 | 5.81 | 14.36 | 13.49 | — |
Current Ratio |
5.63 | 7.01 | 5.14 | 9.42 | 7.73 | 6.03 | 14.68 | 13.56 | — |
Net Debt/EBITDA |
1.11 | 1.60 | 1.40 | 0.25 | 1.43 | 1.69 | 4.43 | 3.98 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.02 | 1.05 | 0.85 | 0.22 | 1.02 | 0.78 | 0.95 | 0.98 | 0.92 |
Capex/Depreciation |
0.00 | (0.70) | (13.11) | 0.00 | 0.00 | (0.11) | (0.18) | (0.45) | 0.00 |
Interest Coverage |
— | — | — | — | — | 237.14 | 188.90 | (82,447.00) | — |
| (79.37%) | (71.47%) | (67.08%) | (299.83%) | (58.51%) | (53.04%) | (77.08%) | (42.66%) | 0.00% | |
| (63.14%) | (55.58%) | (54.11%) | (259.05%) | (49.63%) | (47.24%) | (28.11%) | (47.04%) | (46.02%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(98.00%) | (63.85%) | (78.40%) | (417.97%) | (75.32%) | (69.34%) | (22.62%) | (25.39%) | 0.00% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
2,464.31% | 623.15% | 1,307.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
2,266.13% | 429.83% | 1,445.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
167.28% | 32.57% | 76.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
2.17 | 1.04 | 0.93 | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
(232.94%) | (72.34%) | (79.80%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(232.27%) | (74.87%) | (67.93%) | — | — | — | — | — | — |
Revenue per Share |
0.04 | 0.27 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.97) | (2.46) | (3.37) | (15.09) | (35.41) | (39.55) | (89.00) | (264.30) | (242.67) |
Capex per Share |
0.00 | 0.00 | (0.03) | 0.00 | 0.00 | (0.02) | (0.10) | (0.06) | 0.00 |
Free Cash Flow per Share |
(1.97) | (2.46) | (3.39) | (15.09) | (35.41) | (39.57) | (89.10) | (264.37) | (242.67) |
Cash per Share |
2.23 | 4.15 | 5.97 | 17.37 | 49.87 | 84.22 | 433.49 | 1,138.23 | 0.00 |
Shareholders Equity per Share |
1.90 | 3.50 | 4.69 | 15.48 | 46.52 | 73.22 | 414.01 | 1,059.87 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.90 | 3.50 | 4.69 | 15.48 | 46.52 | 73.22 | 414.01 | 1,059.87 | 0.00 |
Free Cash Flow |
(12.89) | (13.57) | (12.27) | (25.01) | (37.69) | (41.83) | (26.74) | (15.25) | (14.00) |
Working Capital |
12.80 | 20.22 | 18.14 | 26.95 | 49.27 | 77.09 | 123.98 | 61.13 | — |
Capital Expenditures |
— | (0.02) | (0.09) | — | — | (0.03) | (0.03) | 0.00 | — |
Net Current Asset Value |
12.07 | 18.90 | 16.82 | 25.64 | 49.27 | 77.01 | 123.68 | 61.13 | 0.00 |
EV/EBIT |
0.68 | 0.33 | 0.23 | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.01 | 0.16 | — | — | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.36 | 0.27 | 0.08 | 81.04 | 11.37 | 5.96 | 4.09 | 0.34 | 0.00 |
Cash ROIC |
(47.68%) | (32.19%) | (31.82%) | (45.95%) | (36.74%) | (25.14%) | (10.51%) | (12.03%) | 0.00% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
1.03 | 1.51 | 1.26 | 1.31 | 3.14 | 3.34 | 1.96 | 1.96 | — |
Average Assets |
19.96 | 23.31 | 26.40 | 43.49 | 74.81 | 113.21 | 99.82 | 33.01 | 33.01 |
Average Common Equity |
15.87 | 18.13 | 21.30 | 37.58 | 63.45 | 100.82 | 36.40 | 36.40 | — |
Columns are period end dates